[1] Stewart S, Macintyre K, Hole D J, et al. More ‘malignant’
than cancer? Five- year survival following a first admission for
heart failure [J]. Eur J Heart Failure, 2001,3(3):315-322.
[2] James S, Barton D, O'Connell E, et al. Life expectancy for
community-based patients with heart failure from time of diag?
nosis [J]. Int J Cardiol, 2014(178):268-274.
[3] Tang W, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline
for the Management of Heart Failure: A Report of the Ameri?
can [J]. 2013.
[4] 刘志学,胡洋. 《中国心血管病报告2013》在京发布心血管疾
病已成我国重大公共卫生问题[J]. 中国医药导报,2014(26):117.
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.
中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志,
2014,42(2):98-122.
[6] Mills NL, Everson CT, Hockmuth DR. Technical advances in
the treatment of left ventricular aneurysm [J]. Ann Thorac
Surg, 1993,55(3):792-800.
[7] Bruschke AV, Proudfit WL, Sones FM. Progress study of 590
consecutive nonsurgical cases of coronary disease followed 5-9
years. II. Ventriculographic and other correlations [J]. Circula?
tion, 1973,47(6):1147-1153.
[8] 王焱,王斌,常贺,等. 厦门市心血管病医院构建区域协同胸痛
急救网络探索[J]. 中华医院管理杂志,2016,32(6):453-455.
[9] Dai SM, Zhang S, Chen KP, et al. Prognostic factors affecting
the all-cause death and sudden cardiac death rates of post myo?
cardial infarction patients with low left ventricular ejection frac?
tion [J]. Chin Med J (Engl), 2009,122(7):802-806.
[10] Sacks CA, Jarcho JA, Curfman GD. Paradigm shifts in heartfailure
therapy-- a timeline [J]. Engl J Med, 2014,371(11):
989-991.
[11] Firdaus M, Asbury JM, Reynolds DW. A new paradigm of
cardiovascular risk factor modification [J]. Vasc Health Risk,
2005,1(2):101-109.
[12] McMurray JJ, Packer M, Desai AS, et al. Angiotensin—ne?
prilysin inhibition versus enalapril in heart failure [J]. N Engl J
Med, 2014(371)993-1004 .
[13] Swedberg K, Komajda M, B?hm M, et al. Ivabradine and out?
comes in chronic heart failure (SHIFT): a randomised placebocontrolled
study [J]. Lancet, 2010,376(9744):2069–2070.
[14] Dor V, Saab M, Coste P, et al. Left ventricular aneurysm: a
new surgical approach [J]. Thorac Cardiov Surg, 1989,37(1):
11-19.
[15] Dor V. Left Ventricular reconstruction for ischemic heart fail?
ure [J]. Surgical Management of Congestive Heart Failure,
2005:279-299.
[16] Athanasuleas CL, Buckberg GD, Stanley AW, et al. Surgical
ventricular restoration in the treatment of congestive heart fail?
ure due to post- infarction ventricular dilation [J]. J Am Coll
Cardiol, 2004,44(7):1439-1445.
[17] Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused Up?
date Incorporated Into the ACC/AHA 2005 Guidelines for the
Diagnosis and Management of Heart Failure in Adults. A Re?
port of the American College of Cardiology Foundation/Amer?
ican Heart Association Task Force on Practice Guidelines [J].
Circulation, 2009(53):391-479.
[18] Oliveira GH, Alkindi SG, Bezerra HG, et al. Left ventricular
restoration devices [J]. J Cardiovasc Transl Res, 2014,7(3):1-
10.
[19] Costa MA, Jr ME, Sievert H, et al. Percutaneous ventricular
restoration using the parachute device in patients with ischemic
heart failure: three-year outcomes of the PARACHUTE firstin-
human study [J].Circ-heart Fail, 2014,7(5):752-758.
[20] 王建,王斌,肖国胜,等. 经皮左心室分隔术对心尖部室壁瘤形
成的缺血性心力衰竭患者的安全性及疗效评估[J]. 中国循环杂
志,2016,31(8):775-779.